Status | Study |
Active, not recruiting |
Study Name: SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Condition: Malignant Peripheral Nerve Sheath Tumors (MPNST) Sarcoma Date: 2013-11-25 Interventions: Drug: ganetespib 200 mg/m² |
Active, not recruiting |
Study Name: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Condition: Malignant Peripheral Nerve Sheath Tumors MPNST Date: 2012-08-07 Interventions: Drug: everolimus 10 mg tablet |
Active, not recruiting |
Study Name: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Condition: Childhood Alveolar Soft-part Sarcoma Childhood Angiosarcoma Date: 2012-06-06 Interventions: Biological: cixutumumab Given |
Completed |
Study Name: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas Condition: Childhood Alveolar Soft-part Sarcoma Childhood Angiosarcoma Date: 2012-03-27 Interventions: Other: laboratory biomarker analysis Correlative studies |
Terminated |
Study Name: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Condition: Sarcoma Leiomyosarcoma Malignant Per Date: 2011-08-15 Interventions: Drug: Gemcitabine and Docetaxel in Combination with Pazopanib |
Recruiting |
Study Name: Natural History Study of Patients With Neurofibromatosis Type I Condition: Neurofibromatosis Type 1 Malignant Peripheral Nerve Sheath Tumor Date: 2009-06-17 |
Completed |
Study Name: Sorafenib and Dacarbazine in Soft Tissue Sarcoma Condition: Sarcoma Synovial Sarcoma Leiomyosarcoma Date: 2009-02-04 Interventions: Drug: Sorafenib and Dacarbazine Treatment will be administ |
Completed |
Study Name: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Condition: Adult Angiosarcoma Adult Desmoplastic Small Round Cell Tumor Date: 2008-07-19 Interventions: Biological: Cixutumumab Given |
Active, not recruiting |
Study Name: Trial of Dasatinib in Advanced Sarcomas Condition: Rhabdomyosarcoma Malignant Peripheral Nerve Sheath Tumors Date: 2007-04-20 Interventions: Drug: Dasatinib oral agent, continuous dosing, Cycles = 28 days |
Terminated |
Study Name: Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Condition: Malignant Peripheral Nerve Sheath Tumors Date: 2007-01-25 Interventions: Drug: imatinib mesylate |